Date  |
|
| Jan 18, 2022 |
Celcuity Receives FDA Fast Track Designation for Gedatolisib in HR+ / HER2- Metastatic Breast Cancer and Provides Corporate Update |
| Dec 10, 2021 |
Celcuity Presents Updated Results of Phase 1b Study of Gedatolisib in Combination with Palbociclib and Endocrine Therapy for ER+ Advanced Breast Cancer (ABC) at the 2021 San Antonio Breast Cancer Symposium |
| Dec 2, 2021 |
Celcuity to Present at the 2021 San Antonio Breast Cancer Symposium |
| Nov 29, 2021 |
Celcuity Appoints Michael Snitkovsky as VP of Program Management and David Bridge as VP of Quality Assurance and Process Development |
| Nov 15, 2021 |
Celcuity Announces Clinical Trial Collaboration and Supply Agreement with Pfizer to Provide Ibrance(R) (palbociclib) for Planned Phase 3 Clinical Trial |
| Nov 9, 2021 |
Celcuity to Participate in Upcoming Jefferies and Craig-Hallum Investor Conferences |
| Nov 8, 2021 |
Celcuity Inc. Reports Third Quarter 2021 Financial Results and Provides Corporate Update |
| Oct 29, 2021 |
Celcuity Inc. Schedules Release of Third Quarter 2021 Financial Results and Webcast/Conference Call |
| Oct 18, 2021 |
Celcuity Announces Clinical Trial Collaboration with University of Rochester Wilmot Cancer Center and Puma to Study Patients with Breast Cancer Brain Metastases |
| Aug 9, 2021 |
Celcuity Inc. Reports Second Quarter 2021 Financial Results and Provides Corporate Update |
| Aug 5, 2021 |
Celcuity to Participate in the Canaccord Genuity 41st Annual Growth Conference |
| Aug 2, 2021 |
Celcuity Inc. Schedules Release of Second Quarter 2021 Financial Results and Webcast |
| Jul 8, 2021 |
Celcuity to Participate in the William Blair Biotech Focus Conference |
| Jun 28, 2021 |
Celcuity Announces Pricing of Follow-on Offering |
| Jun 28, 2021 |
Celcuity Announces Launch of Follow-on Offering |